Messori A. Updating Efficacy of First-Line Treatments for Chronic Lymphocytic Leukemia: Indirect Comparisons Based on Recent Data Favor the Combination of Acalabrutinib Plus Obinutuzumab. Eur J Haematol 2026 Mar 2. doi: 10.1111/ejh.70150.
PMID: 41771158